Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients

Najjar‐Debbiny, Ronza; Gronich, Naomi; Weber, Regina; Khoury, Johad; Amar, Maisam; Stein, Nili; H. Goldstein, Lee; Saliba, Walid

doi:10.1093/cid/ciac443

Public

Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients

Published in Clinical Infectious Diseases • Jun 2, 2022

Authors:

Ronza Najjar‐Debbiny

Naomi Gronich

Regina Weber

Abstract

BACKGROUND: Paxlovid was granted an Emergency Use Authorization for the treatment of mild to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients (EPIC-HR) trial. Paxlovid effectiveness needs to be ass...

Subject

Medicine

Hazard ratio

Confidence interval

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!